Latomno (Lurasidone)

Lurasidone is an atypical antipsychotic used in psychiatric disorders affecting mood and thought processes.

• Schizophrenia: reduces psychotic symptoms and lowers risk of relapse.
• Bipolar depression: alleviates depressive episodes in bipolar I disorder.
• Schizoaffective disorder (when approved): helps control both mood and psychotic features.

• Lurasidone works by antagonizing dopamine D2 receptors and serotonin 5‑HT2A receptors, while partially agonizing 5‑HT1A receptors and blocking 5‑HT7 receptors. This combined activity modulates dopaminergic and serotonergic neurotransmission, contributing to antipsychotic and mood‑stabilising effects in the central nervous system.

Lurasidone may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Akathisia: inner restlessness or inability to stay still.
• Somnolence: increased sleepiness or fatigue.
• Headache: mild to moderate head pain.
• Weight gain: modest increase in body weight.
• Metabolic changes: slight alterations in glucose or lipid levels.

Serious or Rare Side Effects

• Extrapyramidal symptoms: severe movement disorders.
• Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity.
• Tardive dyskinesia: persistent involuntary movements.
• Orthostatic hypotension: marked drop in blood pressure on standing.
• Seizures: rare occurrence of convulsive episodes.
• Suicidal ideation: emergence or worsening of suicidal thoughts.

Before initiating therapy, consider the following safety measures.

• Cardiovascular assessment: evaluate for QT‑prolongation risk.
• Metabolic monitoring: check fasting glucose and lipid profile periodically.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Elderly patients: start at the lowest effective dose and monitor closely.
• Concomitant CNS depressants: use with caution due to additive sedation.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lurasidone can interact with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase lurasidone plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may substantially reduce efficacy.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines, alcohol): may enhance sedation.
• Antihypertensives: additive effect on blood pressure lowering.
• Anticholinergic agents: may worsen cognitive side effects.
• QT‑prolonging drugs (e.g., certain antiarrhythmics): monitor ECG for interval changes.